Systemic Aspergillosis And Systemic Candidiasis Market Growing Demand, Top Trends, Key Drivers, Companies And Forecast To 2033

The systemic aspergillosis and systemic candidiasis market size has grown strongly in recent years. It will grow from $6.82 billion in 2023 to $7.2 billion in 2024 at a compound annual growth rate (CAGR) of 5.5%. The growth in the historic period can be attributed to increasing incidence of fungal infections, immunocompromised patient population, improved diagnostic technologies, rise in invasive medical procedures, global spread of infections.

The systemic aspergillosis and systemic candidiasis market size is expected to see steady growth in the next few years. It will grow to $8.63 billion in 2028 at a compound annual growth rate (CAGR) of 4.6%. The growth in the forecast period can be attributed to global antifungal resistance surveillance, aging population, telemedicine for remote consultations, patient-centric drug development, digital health solutions for patient management. Major trends in the forecast period include new fungal biomarkers for early detection, emergence of novel antifungal agents, advancements in immunotherapy, innovative drug delivery systems.

Market Overview -
Systemic aspergillosis is the most lethal type of aspergillosis, which develops when the infection spreads to other organs besides the lungs, and systemic candidiasis refers to a range of yeast infections brought on by different species of Candida. Systemic aspergillosis and systemic candidiasis are severe illnesses that can harm the blood, heart, brain, eyes, bones, or other body organs.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=12148&type=smp

Rising Incidence Of Fungal Diseases Spurs Growth In The Systemic Aspergillosis And Systemic Candidiasis Market
The increase in the incidence of fungal diseases is expected to propel the growth of the systemic aspergillosis and systemic candidiasis market going forward. Fungal diseases refer to infections caused by fungi that can affect various body parts, resulting in multiple symptoms and complications. These diseases include cutaneous skin infections, respiratory infections, and systemic infections. Fungal diseases are treated with antifungal medications such as oral azoles, voriconazole, and liposomal amphotericin B. For instance, in March 2023, according to the Centers for Disease Control and Prevention, a US-based national public health agency, in the US, the clinical cases of Candida auris, an emerging fungus, increased from 476 in 2019 to 1,471 in 2021. Screening cases increased threefold from 2020 to 2021, to 4,041. Therefore, the increase in the incidence of fungal disease is driving the growth of the systemic aspergillosis and systemic candidiasis market.

Competitive Landscape -
Major companies operating in the systemic aspergillosis and systemic candidiasis market report are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Abbott Laboratories, Sanofi S.A., GlaxoSmithKline PLC, Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Matinas BioPharma Holdings Inc., Shionogi & Co. Ltd, Cipla Limited, Taj Pharmaceuticals Limited, Basilea Pharmaceutica Ltd., Cidara Therapeutics Inc., T2 Biosystems Inc., Sandoz International GmbH, Grupo Ferrer International S.A., Entasis Therapeutics Inc., NovaDigm Therapeutics Inc., F2G Ltd., Mycovia Pharmaceuticals Inc., ContraFect Corporation, Enzon Pharmaceutical Inc., Pacgen Life Science Corporation, Biosergen AS, N8 Medical LLC

Product Innovation Drive Advancements In The Systemic Aspergillosis And Systemic Candidiasis Markets
Product innovation is a key trend gaining popularity in the systemic aspergillosis and systemic candidiasis markets. Major companies operating in the systemic aspergillosis and systemic candidiasis markets are focused on developing innovative products to sustain their position in the market. For instance, in October 2021, Intas Pharmaceuticals Limited, an India-based pharmaceutical formulation development, manufacturing, and marketing company, launched the world's first Super Bioavailable Itraconazole-SB 100mg under the brand name Itaspor-SB Forte/Subawin. It will cut the dosing in half, and patients can consume it with or without food, with just water. The conventional Itraconazole mainstay medicine to combat fungal infection has a large outcome variance and low patient compliance.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/systemic-aspergillosis-and-systemic-candidiasis-global-market-report

Key Segments -
The systemic aspergillosis and systemic candidiasis market covered in this report is segmented -
1) By Type: Systemic Oral Azoles, Voriconazole, Liposomal Amphotericin B, Topical Antifungal Agents, Other Types
2) By Application: Allergic Bronchopulmonary Aspergillosis (ABPA), Chronic Pulmonary Aspergillosis (CPA), Gastrointestinal Candidiasis, Genitourinary Tract Candidiasis, Other Applications
3) By End User: Clinic, Hospital, Other End Users

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.